Company news
Arrowhead Pharmaceuticals, Inc. news in 2021
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
December 19, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
November 29, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
November 21, 2021
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
November 21, 2021
Arrowhead Announces JNJ-75220795 in Development for NASH
November 16, 2021
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
November 14, 2021
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
November 14, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
November 11, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
November 11, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
October 31, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
October 31, 2021
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
October 24, 2021
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
October 11, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
September 29, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
September 28, 2021
Arrowhead Earns $10 Million Phase 1 Milestone Payment
September 27, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
August 31, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
August 4, 2021
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
July 28, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
July 13, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 13, 2021
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
July 5, 2021
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
July 1, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
June 29, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
June 25, 2021
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
June 24, 2021
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
June 22, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
June 20, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
June 2, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
June 1, 2021
Arrowhead Earns $10 Million Option Exercise Fee
May 17, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
May 3, 2021
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
April 27, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
April 15, 2021
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
April 14, 2021
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
February 28, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
February 3, 2021
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
January 24, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
January 18, 2021